Tavros Therapeutics
Genetically Targeted Cancer Treatment
Formed in 2019, Tavros Therapeutics is a precision oncology company discovering targeted therapies exploiting tumors’ genetic vulnerabilities. Tavros aims to understand how cancer evolves so it can better identify unique druggable vulnerabilities. By targeting the right new drugs to the right patients, its ultimate goal is to improve clinical trial success rates, patient outcomes, and quality of life.
Applying deep expertise in cancer biology with pioneering high-throughput functional genomic approaches, Tavros has built EVOLVETM, a bi-directional CRISPR platform that simultaneously tests thousands of causal relationships between genes at massively powered scale to identify paired genetic interactions that form the basis for breakthrough targets and first-in-class cancer drugs.
EVOLVE is the first directly causal synthetic lethality platform. Synthetic lethality is one of the most promising areas of genetically targeted cancer treatment. Tavros’ EVOLVE discovery engine overcomes key shortcomings in first-generation approaches with unprecedented speed and scalability. Tavros is leveraging EVOLVE to: 1) build a robust and highly innovative pipeline of small-molecule precision therapeutics exploiting tumor-specific dependencies; and 2) partner a subset of programs exploring traditionally “undruggable” targets to identify high-value targets and/or augment the efficacy of emerging compounds.
Tavros has already made progress building a foundation of partnerships and collaborations, including with Zentalis Pharmaceuticals, OpenBench, and most recently, a five-year agreement worth up to $930 million with Vividion Therapeutics, a wholly owned subsidiary of Bayer Pharma. In this partnership, the companies will work to define novel drug targets and biomarkers and clinically position existing compounds. These relationships support the company’s growth, expedite its scientific R&D, reinforce the potential promise of Tavros’ unique approach, and expand its future potential clinical impact.
